ClinicalTrials.gg
CompletedNCT02791815Updated Oct 13, 2016

Potential Pharmacokinetic Interaction Between Selexipag and Midazolam in Healthy Male Subjects

A Phase 1 interventional study of Midazolam and Selexipag in Healthy Subjects, sponsored by Actelion. Completed at 1 site in France. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-13.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The primary purpose of this study is to evaluate the effect of repeated doses of selexipag on the pharmacokinetics of a single oral dose of midazolam (i.e., how long and how much midazolam is present in the blood)

Read the detailed description

In order to exclude an inductive effect of selexipag in the gastrointestinal tract, this study aims at investigating the effect of selexipag on the PK of midazolam, a sensitive substrate of both hepatic and intestinal cytochrome P450 3A4 (CYP3A4).

02

Conditions studied

  • Healthy Subjects

Keywords

  • selexipag
  • pharmacokinetics
  • midazolam
03

In context

Lead sponsor

Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.

First submitted before Actelion became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Signed form
  • Age from 18 to 45 years (inclusive) at screening
  • (BMI) from 18.0 to 28.0 kg/m2 (inclusive) at screening
  • Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests

Key Exclusion Criteria:

  • Any to the study treatments
  • History or clinical evidence of any disease or medical / surgical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the absorption, distribution, metabolism or excretion of the study treatments
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Sequence AB

    Subjects participate in two study periods: During the first period, they receive a single oral dose of midazolam on Day 1. During the second period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. There is a washout period of 14 to 21 days between the two periods.

    Drug: Midazolam · Drug: Selexipag

  • Experimental
    Sequence BA

    Subjects participate in two study periods: During the first period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. During the second period, they receive a single oral dose of midazolam on Day 1. There is a washout period of 14 to 21 days between the two periods.

    Drug: Midazolam · Drug: Selexipag

Interventions

  • Single oral dose of 7.5 mg midazolam (tablet)

  • Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )

    Also known as: ACT-293987

06

What researchers measure

Primary outcomes

  1. Cmax of midazolam following administration of midazolam alone and in combination with selexipag

    Cmax is the maximum observed plasma concentration and is directly derived from the individual plasma concentration time curves of midazolam

    Time frame: From pre-dose up to 24 hours after midazolam admisnitration for each treatment period

  2. AUC(0-inf) of midazolam following administration of midazolam alone and in combination with selexipag

    AUC(0-inf) is the area under the plasma concentration-time curves of midazolam, calculated from time 0 (pre-dose) to the extrapolated infinite time

    Time frame: From pre-dose up to 24 hours after midazolam admisnitration for each treatment period

Secondary outcomes

  1. Cmax of 1-hydroxymidazolam following administration of midazolam alone and in combination with selexipag

    Time frame: From pre-dose up to 24 hours after midazolam admisnitration

  2. AUC(0-inf) of 1-hydroxymidazolam following administration of midazolam alone and in combination with selexipag

    Time frame: From pre-dose up to 24 hours after midazolam admisnitration

  3. tmax of midazolam and 1-hydroxymidazolam following administration of midazolam alone and in combination with selexipag

    tmax is the time to reach Cmax of midazolam and its metabolite (1-hydroxymidazolam), respectively

    Time frame: From pre-dose up to 24 hours after midazolam admisnitration

  4. t½ of midazolam and 1-hydroxymidazolam following administration of midazolam alone and in combination with selexipag.

    t½ is the terminla half-life of midazolam and its metabolite (1-hydroxymidazolam), and corresponds to the period of time required for the concentration levels of midazolam and its metabolite to be reduced by one-half, respectively

    Time frame: From pre-dose up to 24 hours after midazolam admisnitration

  5. Trough concentration of selexipag and its metabolite ACT-333679 at steady-state

    Trough concentrations are measured before morning administration of selexipag

    Time frame: Days 1, 4, 7, 10,12 and 13

Other outcomes

  1. Incidence of treatment-emergent adverse events and serious adverse events

    A treatment-emergent AE is any AE temporally associated with the use of a study treatment, whether or not considered related to the study treatment

    Time frame: Up to 39 days (from Day 1 of Period 1 to end of study of Period 2)

07

Study locations

1 site
  • Investigator Site
    Gieres, 38610, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2016
First posted
Jun 7, 2016
Start
Jul 2016
Primary completionActual
Sep 2016
CompletionActual
Sep 2016
Last update
Oct 13, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02791815
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Jun 7, 2016
Start date
Jul 2016
Primary completion
Sep 2016
Completion
Sep 2016
Last update
Oct 13, 2016

Study contacts

Pierre-Eric Juif, PhD
study director · Actelion

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Midazolam · Selexipag

Start the discussion